These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17361254)

  • 21. Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial.
    Bunnag D; Malikul S; Chittamas S; Chindanond D; Harinasuta T; Fernex M; Mittelholzer ML; Kristiansen S; Sturchler D
    Southeast Asian J Trop Med Public Health; 1992 Dec; 23(4):777-82. PubMed ID: 1298089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acute paranoid hallucinatory psychosis following mefloquine prophylaxis (Lariam)].
    Krüger E; Grube M; Hartwich P
    Psychiatr Prax; 1999 Sep; 26(5):252-4. PubMed ID: 10535096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
    Galor A; Ference SJ; Singh AD; Lee MS; Stevens GH; Perez VL; Peereboom DM
    Am J Ophthalmol; 2007 Jul; 144(1):45-49. PubMed ID: 17601426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malaria, mefloquine and the mind.
    Ingram RJ; Ellis-Pegler RB
    N Z Med J; 1997 Apr; 110(1042):137-8. PubMed ID: 9152353
    [No Abstract]   [Full Text] [Related]  

  • 25. Mefloquine-induced eosinophilic pneumonia.
    Katsenos S; Psathakis K; Nikolopoulou MI; Constantopoulos SH
    Pharmacotherapy; 2007 Dec; 27(12):1767-71. PubMed ID: 18041895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study.
    Ollivier L; Tifratene K; Josse R; Keundjian A; Boutin JP
    Ann Trop Med Parasitol; 2004 Sep; 98(6):639-41. PubMed ID: 15324471
    [No Abstract]   [Full Text] [Related]  

  • 27. [Malaria chemoprophylaxis: tolerance and compliance with mefloquine and proguanil/chloroquine combination in French tourists].
    Carme B; Péguet C; Nevez G
    Bull Soc Pathol Exot; 1997; 90(4):273-6. PubMed ID: 9479468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy.
    Vanhauwere B; Maradit H; Kerr L
    Am J Trop Med Hyg; 1998 Jan; 58(1):17-21. PubMed ID: 9452285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychotic mania associated with mefloquine in a bipolar patient.
    Brumbaugh M; Price P; Fagan N; Hsieh H
    South Med J; 2008 May; 101(5):550-1. PubMed ID: 18414180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.
    Overbosch D; Schilthuis H; Bienzle U; Behrens RH; Kain KC; Clarke PD; Toovey S; Knobloch J; Nothdurft HD; Shaw D; Roskell NS; Chulay JD;
    Clin Infect Dis; 2001 Oct; 33(7):1015-21. PubMed ID: 11528574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Polymorphism at the MDR1 locus as a cause of mefloquine-induced psychosis].
    Zaigraykina N; Potasman I
    Harefuah; 2010 Sep; 149(9):583-4, 620, 619. PubMed ID: 21302473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neuropsychiatric symptoms caused by mefloquine (report of several cases)].
    Murai Z; Baran B; Tolna J; Szily E; Gazdag G
    Orv Hetil; 2005 Jan; 146(3):133-6. PubMed ID: 15693445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New ways of treating and preventing malaria: mefloquine (Lariam)].
    Kollaritsch H; Kremsner PG
    Wien Klin Wochenschr; 1987 May; 99(10):346-51. PubMed ID: 3496715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malaria prophylaxis and the media.
    Clift S; Grabowski P
    Lancet; 1996 Aug; 348(9023):344. PubMed ID: 8709720
    [No Abstract]   [Full Text] [Related]  

  • 35. The adverse effects of mefloquine in deployed military personnel.
    Adshead S
    J R Nav Med Serv; 2014; 100(3):232-7. PubMed ID: 25895400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases].
    Lebain P; Juliard C; Davy JP; Dollfus S
    Encephale; 2000; 26(4):67-70. PubMed ID: 11064842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision.
    Senn N; D'Acremont V; Landry P; Genton B
    Am J Trop Med Hyg; 2007 Dec; 77(6):1010-4. PubMed ID: 18165513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers.
    Rombo L; Angel VH; Friman G; Hellgren U; Mittelholzer ML; Stürchler D
    Trop Med Parasitol; 1993 Sep; 44(3):254-6. PubMed ID: 8256106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events.
    van Riemsdijk MM; Sturkenboom MC; Ditters JM; Ligthelm RJ; Overbosch D; Stricker BH
    Clin Pharmacol Ther; 2002 Sep; 72(3):294-301. PubMed ID: 12235450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term malaria prophylaxis with mefloquine: a study of adverse drug reactions].
    El Jaoudi R; Benziane H; Khabbal Y; Elomri N; Lamsaouri J; Cherrah Y
    Therapie; 2010; 65(5):439-45. PubMed ID: 21144479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.